Wellington Management Group LLP Boosts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Wellington Management Group LLP grew its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRAFree Report) by 18.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 94,112 shares of the company’s stock after buying an additional 14,676 shares during the quarter. Wellington Management Group LLP owned 0.22% of Tyra Biosciences worth $1,296,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in TYRA. UBS Group AG raised its position in shares of Tyra Biosciences by 3,841.8% during the 4th quarter. UBS Group AG now owns 3,587 shares of the company’s stock valued at $27,000 after buying an additional 3,496 shares in the last quarter. Barclays PLC raised its position in Tyra Biosciences by 544.1% in the 4th quarter. Barclays PLC now owns 3,581 shares of the company’s stock worth $27,000 after purchasing an additional 3,025 shares during the period. Simplex Trading LLC raised its position in Tyra Biosciences by 198.1% in the 3rd quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock worth $27,000 after purchasing an additional 1,335 shares during the period. Royal Bank of Canada raised its position in Tyra Biosciences by 206.9% in the 2nd quarter. Royal Bank of Canada now owns 2,277 shares of the company’s stock worth $39,000 after purchasing an additional 1,535 shares during the period. Finally, Citigroup Inc. purchased a new position in Tyra Biosciences in the 2nd quarter worth $71,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Analyst Ratings Changes

TYRA has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research report on Thursday, March 21st. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price (up previously from $19.00) on shares of Tyra Biosciences in a research report on Wednesday, March 20th. Finally, Bank of America cut shares of Tyra Biosciences from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $25.00 to $15.00 in a research report on Friday, December 15th.

Check Out Our Latest Stock Analysis on TYRA

Tyra Biosciences Trading Up 0.6 %

TYRA stock opened at $16.40 on Friday. The firm’s 50-day moving average price is $17.38 and its two-hundred day moving average price is $14.59. Tyra Biosciences, Inc. has a 12-month low of $10.38 and a 12-month high of $20.67. The stock has a market capitalization of $861.33 million, a price-to-earnings ratio of -10.19 and a beta of 1.19.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, COO Daniel Bensen sold 1,501 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $20.00, for a total value of $30,020.00. Following the transaction, the chief operating officer now owns 451,480 shares in the company, valued at $9,029,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 15,816 shares of company stock worth $298,165. 18.40% of the stock is currently owned by company insiders.

Tyra Biosciences Company Profile

(Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies.

Read More

Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRAFree Report).

Institutional Ownership by Quarter for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.